Soleno Therapeutics Announces the Passing of Board Member William G. Harris

Core Points - Soleno Therapeutics announced the passing of William G. "Bill" Harris, a long-serving member of its Board of Directors and Chairman of the Audit Committee since June 2014 [1][2] - Dr. Anish Bhatnagar, CEO and Chairman of the Board, expressed condolences and highlighted Mr. Harris's integrity and contributions to the company during challenging times [2] - Andrew Sinclair is expected to succeed Mr. Harris as Chair of the Audit Committee, qualifying as an "audit committee financial expert" as per SEC and Nasdaq rules [3] Company Overview - Soleno Therapeutics focuses on developing and commercializing novel therapeutics for rare diseases [4] - The company's first commercial product, VYKAT™ XR (diazoxide choline) extended-release tablets, was approved by the FDA on March 26, 2025, for treating hyperphagia in individuals with Prader-Willi syndrome aged 4 and older [4]